Pharmasset, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 12   

Articles published

VRUS 0.0000
price chart
Promotion to CEO of Chimerix comes with perks
From January 2007 to January 2012, Berrey served as chief medical officer at Pharmasset Inc., a company that focused on treatment of hepatitis C. From January 2004 to January 2007, she served as vice president over Viral Diseases, Clinical Pharmacology ...
Related articles »  
Payers, providers, patients � even politicians � attacking Gilead over $1000 ...
Gilead also wants to recoup its $11 billion acquisition in 2011 of Pharmasset Inc., whose portfolio ended up producing Sovaldi, and pay for future research and development.
Related articles »  
Chimerix CEO Resigns, Names Replacement
Before joining Chimerix, Berrey was Chief Medical Officer at Pharmasset, Inc., a company that focused on the development of nucleotide analogs for the treatment of hepatitis C, from 2007 until its acquisition by Gilead Sciences, Inc. in January 2012.
Chimerix Announces Appointment of M. Michelle Berrey, MD, MPH as Chief ...  Wall Street Journal
Related articles »  
Court Report
Defendants: Gilead Sciences Inc.; Gilead Pharmasset LLC; Gilead Sciences Ltd. Infringement of U.S. Patent No.
Cost of Hepatitis C drug spurs revolt
Gilead also wants to recoup its $11 billion acquisition in 2011 of Pharmasset Inc., whose portfolio ended up producing Sovaldi, and pay for future research and development.
A Physician-Businessman's Views Of Gilead, With Emphasis On Sovaldi  Seeking Alpha
Related articles »  
Professor Raymond Schinazi Joins Board of reViral as Non-executive Director
He is also the founder of five biotechnology companies including Pharmasset, Inc. (VRUS; acquired by Gilead in 2012 for 11.4 B).
How Did High Flyers Turn Into Soul Searchers? Maxim Analyst Jason Kolbert On ...
The rise of stocks like Pharmasset Inc. [acquired by Gilead] helped drive this trend. The success of Intercept Pharmaceuticals Inc. (ICPT) is another example of the risks and rewards that the sector offers to investors [which make it unique in the field].
Chimerix CEO steps down, replacement named [The Herald-Sun, Durham, NC :: ]
Before that, she was chief medical officer at Pharmasset, Inc. from 2007 until its acquisition by Gilead Sciences Inc .
Gilead takes political heat over its $84000 hepatitis C drug
Gilead snagged Sovaldi, a potential cure for hepatitis C patients, as part of its $11 billion, January 2011 acquisition of Pharmasset Inc. Less than three years later, in December, it won initial FDA approval of the drug in combination with today's ...
Related articles »  
Gilead Sciences: Strong Long-Term Growth At A Bargain
Solvaldi is the drug that Gilead bought with its aforementioned acquisition of Pharmasset. It was approved at the end of 2013 and is expected to do revenue well into the multi-billions in its first year (2014).
Related articles »